Teva says Allergan deal to close ‘any time’, expects U.S. antitrust clearance
NEW YORK/TEL AVIV (Reuters) – Teva Pharmaceutical Industries Ltd said on Wednesday it expected its $40 billion deal to buy Allergan Plc's generics business to close "at any time," even as the companies extended the deadline for completing the transaction to October to allow more time for the U.S. antitrust review. "We expect the closing of the … generics deal at any time now," Teva Chief Executive Officer Erez Vigodman said during a conference call with analysts to discuss the Israeli drugmaker&039;s financial outlook. The deal closing is contingent on clearance from the U.S. Federal Trade Commission (FTC), the antitrust regulator reviewing the deal, which the companies said they expect at any time.
